Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Since the discovery of cyclic nucleotide phosphodiesterase 30 years ago, there have been major advances in our knowledge of this group of isoenzymes. Five families, each composed of several isoforms and having differing tissue distributions, have been described. David Nicholson and colleagues compare the tissue distribution of phosphodiesterase isoenzymes and discuss the differential effects of inhibition of particular isoenzymes, with differing subcellular localization, on tissue function. They also review the potential use of isoenzyme selective phosphodiesterase inhibitors in a range of clinical disorders such as heart failure, asthma, depression and dementia.
Nicholson
C D
CD
Department of Pharmacology, Organon Laboratories Ltd, Newhouse, UK.
Challiss
R A
RA
Shahid
M
M
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000037:antagonists & inhibitors / Q000502:physiology*; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007527:Isoenzymes / Q000502:physiology*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy
D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases